The landscape of dementia prognosis has developed radically with the appearance of innovative biomarkers, including amyloid PET scans, tau imaging, and blood-primarily based tests that could detect Alzheimer's pathology several years just before signs and symptoms emerge. Whilst these technological advances stand for impressive progress in knowledg